AbbVie Reports long-term follow-up Data for Onasemnogene abeparvovec in COPD

AbbVie today announced long-term follow-up results for onasemnogene abeparvovec in patients with COPD. The study demonstrated that onasemnogene abeparvovec improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of COPD and support the continued development of onasemnogene abeparvovec in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.